CoChat

Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses

Open access
Zhong, Li, Li, Baozheng, Mah, Cathryn S., Govindasamy, Lakshmanan, Agbandje-McKenna, Mavis, Cooper, Mario, Herzog, Roland W., Zolotukhin, Irene, Warrington, Kenneth H., Weigel-Van Aken, Kirsten A., Hobbs, Jacqueline A., Zolotukhin, Sergei, Muzyczka, Nicholas, Srivastava, Arun · 2008 · Proceedings of the National Academy of Sciences

The DOI matches its Crossref record; 51 of the 53 references it cites were found in a registry or an index.

Abstract

Recombinant adeno-associated virus 2 (AAV2) vectors are in use in several Phase I/II clinical trials, but relatively large vector doses are needed to achieve therapeutic benefits. Large vector doses also trigger an immune response as a significant fraction of the vectors fails to traffic efficiently to the nucleus and is targeted for degradation by the host cell proteasome machinery. We have reported that epidermal growth factor receptor protein tyrosine kinase (EGFR-PTK) signaling negatively affects transduction by AAV2 vectors by impairing nuclear transport of the vectors. We have also observed that EGFR-PTK can phosphorylate AAV2 capsids at tyrosine residues. Tyrosine-phosphorylated AAV2 vectors enter cells efficiently but fail to transduce effectively, in part because of ubiquitination of AAV capsids followed by proteasome-mediated degradation. We reasoned that mutations of the surface-exposed tyrosine residues might allow the vectors to evade phosphorylation and subsequent ubiquitination and, thus, prevent proteasome-mediated degradation. Here, we document that site-directed mutagenesis of surface-exposed tyrosine residues leads to production of vectors that transduce HeLa cells ≈10-fold more efficiently in vitro and murine hepatocytes nearly 30-fold more efficiently in vivo at a log lower vector dose. Therapeutic levels of human Factor IX (F.IX) are also produced at an ≈10-fold reduced vector dose. The increased transduction efficiency of tyrosine-mutant vectors is due to lack of capsid ubiquitination and improved intracellular trafficking to the nucleus. These studies have led to the development of AAV vectors that are capable of high-efficiency transduction at lower doses, which has important implications in their use in human gene therapy.

Overview

Integrity signals

Registry

Crossref · 10.1073/pnas.0802866105

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 51 references

Cited by

Items 201–300 of 567

Metadata

Authors
Zhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R. W., Zolotukhin, I., Warrington, K. H., Weigel-Van Aken, K. A., Hobbs, J. A., Zolotukhin, S., Muzyczka, N., & Srivastava, A.
Affiliations
  • *Division of Cellular and Molecular Therapy, Department of Pediatrics,
  • Powell Gene Therapy Center and Genetics Institute,
  • University of Florida Health (US)
  • UF Health Cancer Center (US)
Venue
Proceedings of the National Academy of Sciences
Published
2008-06-03
Volume
105
Issue
22
Pages
7827-7832
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2122236774
Cited by
558
References
53
Citations by year
2026: 14 · 2025: 15 · 2024: 30 · 2023: 31 · 2022: 29 · 2021: 43 · 2020: 38 · 2019: 31 · 2018: 27 · 2017: 34 · 2016: 29 · 2015: 38 · 2014: 34 · 2013: 44 · 2012: 24
FWCI
18.28
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • American Heart Association
  • National Institutes of Health (Project 3)
  • National Heart, Lung, and Blood Institute (P01-HL51811, P01HL059412, P01HL051811, R01 HL-07691, R01HL065570, R01HL-65570, P01HL078810)
  • National Institute of General Medical Sciences (R01GM082946)
  • National Institute of Allergy and Infectious Diseases (R01AI051390)
  • National Institute of Diabetes and Digestive and Kidney Diseases (P01DK058327, R01DK062302)
  • National Institute of Biomedical Imaging and Bioengineering (R01EB002073)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
Keywords
tyrosine mutations, proteasomal degradation, nuclear transport, transduction efficiency, factor IX, gene therapy vectors, hepatocytes
MeSH terms
Dependovirus, Animals, Capsid, Cell Nucleus, Genetic Vectors, HeLa Cells, Humans, Mice, Inbred C57BL, Phosphorylation, Transduction, Genetic, Tyrosine, Genetic Therapy, Point Mutation, Hepatocytes, Mice, Ubiquitination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.